Pressmeddelanden

REG MAR
Eevia Board Terminates Process for Reverse Takeover Further to the press release Eevia made on December 2 about Eevia Health Plc ("Eevia" or "The Company") receiving a proposal for a reverse takeover (RTO) from Stemtech Corporatio...
Eevia Health Plc receives a MSEK 1,8 (KUSD 169) sales order Eevia Health ("Eevia" or "The Company") received a MSEK 1,849 / KUSD 169 blanket sales order for the elderberry extract Feno-Sambucus™ 7 ORGANIC from a distributor in the US.
REG MAR
Eevia is subject to a possible reverse takeover Eevia Health Plc ("Eevia" or "The Company") received a proposal for a reverse takeover (RTO) from Stemtech Corporation[1] ("Stemtech"), a US company, on November 10. The proposal...
REG MAR
Eevia Health Plc: Eevia Health Plc Interim Report Q3 - 2024 The Board and CEO of Eevia Health Plc present the Interim financial report for quarter 3, 2024.  Financial developments and significant events in the third quarter of 2024: · Net...
Eevia revises financial targets The new Board of Eevia Health Plc ("Eevia" or "The Company") has approved a new strategic business plan for 2025 - 2026. The new strategy is also a turnaround plan for the Compan...
REG
Eevia revises date for release of Interim report Q3-2024 Eevia Health Plc ("Eevia" or "The Company") will publish its Interim report for the third quarter on November 29 due to the onboarding of a new Board and one large unforeseen urg...
Visa fler pressmeddelanden

Rapporter

Video

Finansiell kalender

Bokslutskommuniké 2024 Bokslutskommuniké
Delårsrapport Q1 2025 Delårsrapport
Delårsrapport Q2 2025 Delårsrapport

Om Eevia Health

Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.

Webbplats
eeviahealth.com/investors

Handelsinformation

Kurs ()
Förändring ()
Marknad Spotlight stock market Kortnamn EEVIA ISIN-kod FI4000496658

IR-Kontakt

Stein Ulve IR-kontakt [email protected]